Article Figures & Data
Figures
- Figure 1.
Correlation among ALC, NLR and CYT in BC patients. (A) The treatment and sampling protocol. (B) The correlation between ALC and NLR in advanced BC patients. Left, before treatment (n, number of samples); middle, during treatment (n, number of samples); right, the correlation between the ALC-increase ratio and NLR-decrease ratio (n, number of patients). (C) The correlation between ALC and NLR in advanced BC patients according to the anticancer drugs. n, number of samples. (D) The correlation between ALC, NLR and CYT score in BC patients. The cutoff values of ALC, NLR and CYT scores were 1700, 1.75 and 31.56, respectively. n, number of patients. ALC and NLR were expressed relative to the level prior to treatment with each line of therapy (BS=1.0). *p<0.05. ALC, Absolute lymphocyte count; NLR, neutrophil-to-lymphocyte ratio; CYT, cytolytic activity; BC, breast cancer; BS, baseline.
- Figure 2.
The sequential changes in ALC and NLR during chemotherapy in advanced BC patients. (A) The sequential changes in ALC and NLR during chemotherapy. (B) The ratio of changes in ALC or NLR during chemotherapy according to the hospitals. Left, Ueo; middle, Kyushu; right, total. n, number of patients. (C) ALC or NLR during chemotherapy relative to before chemotherapy. n, number of samples. ALC and NLR were expressed relative to the level prior to treatment with each line of therapy (BS=1.0). *p<0.05. ALC, Absolute lymphocyte count; NLR, neutrophil-to-lymphocyte ratio; BC, breast cancer; EC, epirubicin plus cyclophosphamide; PB, paclitaxel plus bevacizumab; Eri, eribulin; BS, baseline.
- Figure 3.
The sequential changes in ALC and NLR during chemotherapy in advanced BC patients with disease progression. (A) The ratio of changes in ALC or NLR during chemotherapy. n, number of patients. (B) ALC or NLR during chemotherapy relative to before chemotherapy. n, number of samples. ALC and NLR were expressed relative to the level prior to treatment with each line of therapy (BS=1.0). *p<0.05. ALC, Absolute lymphocyte count; NLR, neutrophil-to-lymphocyte ratio; BC, breast cancer; EC, epirubicin plus cyclophosphamide; PB, paclitaxel plus bevacizumab; Eri, eribulin; BS, baseline.
- Figure 4.
Differences of changes in ALC and NLR during chemotherapy between front and later lines in advanced BC patients. (A) The ratio of change in ALC or NLR during chemotherapy of 172 advanced BC patients. (B) The ratio of change in ALC or NLR during chemotherapy according to the anticancer drugs. Front line, 1st-2nd line; Later line, 3rd-4th line. ALC, Absolute lymphocyte count; NLR, neutrophil-to-lymphocyte ratio; BC, breast cancer; EC, epirubicin plus cyclophosphamide; PB, paclitaxel plus bevacizumab; Eri, eribulin; n, number of patients.
- Figure 5.
The difference of change in ALC and NLR during chemotherapy between responders and non-responders to chemotherapy in advanced BC patients with disease progression. (A) The ratio of change in ALC or NLR during chemotherapy of 101 advanced BC patients with disease progression. (B) The ratio of change in ALC or NLR during chemotherapy according to the anticancer drugs. Responder, TTF ≥3months; non-responder, TTF <3 months. *p<0.05. ALC, Absolute lymphocyte count; NLR, neutrophil-to-lymphocyte ratio; BC, breast cancer; TTF, time to treatment failure; n, number of patients.
- Figure 6.
Kaplan-Meier PFS curve of advanced BC patients during chemotherapy based on the change in ALC or NLR. (A) PFS is based on the ratio of change in ALC or NLR of 172 BC patients. (B) PFS based on the ratio of change in ALC or NLR according to the anticancer drugs. *p<0.05. PFS, Progression-free survival; BC, breast cancer; ALC, absolute lymphocyte count; NLR, neutrophil-to-lymphocyte ratio; EC, epirubicin plus cyclophosphamide; PB, paclitaxel plus bevacizumab; Eri, eribulin; n, number of patients.
Tables
In this issue
Jump to section
Related Articles
Cited By...
- No citing articles found.